Specialty Drug Pipeline Reviews to help you
Control Medical Drug Spend

Sign up for RJ Health Drug Alerts below to access our collection of reviews.

If you are already a Drug Alerts subscriber, simply re-enter your email to be redirected.

Our current collection of specialty drug pipeline reviews available to Drug Alerts subscribers includes:

Tildrakizumab

2018 Drug Pipeline Review
PDUFA: March 26, 2018

Ibalizumab-uiyk (Trogarzo™)

2018 Drug Pipeline Review
PDUFA: April 3, 2018

Burosumab

2018 Drug Pipeline Review
PDUFA: April 17, 2018

Herceptin (Trastuzumab) Biosimilars

2018 Drug Pipeline Review
PDUFA: April 30, 2018

Erenumab

2018 Drug Pipeline Review
PDUFA: May 17, 2018

Rituxan (Rituximab) Biosimilars

2018 Drug Pipeline Review
PDUFA: July 12, 2018

Mogamulizumab-kpkc

2018 Drug Pipeline Review
PDUFA: June 4, 2018
FDA Approval: August 8, 2018

Patisiran

2018 Drug Pipeline Review
PDUFA: August 11, 2018
FDA Approval: August 10, 2018

Lanadelumab-flyo (Takhzyro™)

2018 Drug Pipeline Review
PDUFA: August 26, 2018
FDA Approval: August 23, 2018

Volanesorsen Sodium

2018 Drug Pipeline Review
PDUFA: August 30, 2018

Moxetumomab pasudotox (Lumoxiti™)

2018 Drug Pipeline Review
PDUFA: September 9, 2018
FDA Approval: September 13, 2018

Fremanezumab-vfrm (Ajovy™)

2018 Drug Pipeline Review
PDUFA: June 16, 2018
FDA Approval: September 14, 2018

Inotersen sodium

2018 Drug Pipeline Review
PDUFA: October 6, 2018